

TO:LAW OFFICE OF JOHN K. PIKE, PLLC COMPANY:2121 EISENHOWER AVENUE

**UNITED STATES PATENT AND TRADEMARK OFFICE**UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

APRIL 28, 2009

500845574A

PTAS

LAW OFFICE OF JOHN K. PIKE, PLLC
2121 EISENHOWER AVENUE
SUITE 200
ALEXANDRIA, VA 22314

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT SERVICES BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 04/28/2009

REEL/FRAME: 022597/0235

NUMBER OF PAGES: 19

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).
DOCKET NUMBER: 64DIV 56DIV 57DIV 57DVCON

ASSIGNOR:

THE PICOWER INSTITUTE FOR MEDICAL
RESEARCH

DOC DATE: 04/15/2002

ASSIGNEE:

CYTOKINE PHARMASCIENCES, INC.
150 SOUTH WARNER ROAD
SUITE 420
KING OF PRUSSIA, PENNSYLVANIA 19406

SERIAL NUMBER: 11225124

FILING DATE: 09/14/2005

PATENT NUMBER:

ISSUE DATE:

TITLE: KIT COMPRISING AN ANTIBODY THAT BINDS HUMAN MIF

SERIAL NUMBER: 09670216

FILING DATE: 09/25/2000

PATENT NUMBER: 6596851

ISSUE DATE: 07/22/2003

TITLE: INDUCIBLE PHOSPHOFRUCTOKINASE AND THE WARBURG EFFECT

TO:LAW OFFICE OF JOHN K. PIKE, PLLC COMPANY:2121 EISENHOWER AVENUE

022597/0235 PAGE 2

SERIAL NUMBER: 08471586

FILING DATE: 06/06/1995

PATENT NUMBER: 6080407

ISSUE DATE: 06/27/2000

TITLE: DIAGNOSTIC ASSAYS FOR MIF

SERIAL NUMBER: 09557823

FILING DATE: 04/25/2000

PATENT NUMBER: 6998238

ISSUE DATE: 02/14/2006

TITLE: METHOD FOR DETERMINING MIF CONTENT

ASSIGNMENT SERVICES BRANCH
PUBLIC RECORDS DIVISION

AGREEMENT

This Agreement, executed by The Picower Institute for Medical Research, of Manhasset, New York ("Institute" herein) and Cytokine PharmaSciences, Inc., of King of Prussia, Pennsylvania ("CPSI" herein) is effective as of April 15, 2002.

Whereas, the Institute and CPSI are parties to an existing license agreement (the "License Agreement") originally dated September 5, 1991; and

Whereas there are a substantial number of patents and patent applications subject to the License Agreement owned in whole or in part by the Institute; and

Whereas, the Institute has ceased to fund research and desires to cease operations without limiting the value of said patents and patent applications in any way:

NOW THEREFORE, THE PARTIES, DESIRING TO BE LEGALLY BOUND, AGREE AS FOLLOWS:

1. The License Agreement is hereby terminated, with neither party having any liability or obligation to the other thereunder.
2. The Institute does hereby transfer, set over and assign to CPSI the Institute's entire right, title and interest in and to all patents and patent applications set forth on Schedule A hereto. The Institute has been responsible for prosecution of said applications and maintenance of said patents and patent applications. By execution of this agreement, CPSI agrees, to prosecute said patent applications and maintain said patents and patent applications, to the degree commercially reasonable under the circumstances.
3. To the extent the Institute owns any rights in and to technology not the subject of a patent or application, but related to the practice of subject matter claimed in the patents and patent applications set forth in Schedule A, the entirety of the Institutes rights therein is hereby assigned to CPSI.
4. The Institute has previously had possession of certain inventors notebooks and other records pertinent to the inventions disclosed and claimed in the patents and patent applications set forth in Schedule A. The Institute has provided CPSI with access to said notebooks and other records, together with such indexes or schedules thereof already in existence. Those of such notebooks, records, indexes and schedules designated by CPSI on or before the date of this Agreement have been or will be transferred to the safekeeping of CPSI at the expense of CPSI.
5. The Institute has previously created and maintained, at private facilities, strains of created laboratory animals representing significant intellectual property pertinent or otherwise

relevant to the patents and patent applications set forth in Schedule A. The Instituto hereby transfers to CPSI its entire right in and to said laboratory animals. CPSI hereby accepts such transfer.

6. [REDACTED]

[REDACTED]
[REDACTED]
attributable to a Product or Service (as hereinafter defined) sold by CPSI or any one or more affiliates of CPSI, less returns, promotional allowances, freight, transportation insurance, charges for returnable containers, import or export taxes, any tax or government charge levied on the sale, transportation or delivery of such Product or Service borne by the seller thereof, commissions to third parties and customary chargebacks and trade discounts actually taken.

"Product or Service" means any product or service falling within the claims of the patents and patent applications set forth on Schedule A hereto, unless those claims have been found invalid by a court of competent jurisdiction without appeal, or said patent or patent application has expired or been allowed to lapse. "Royalty Revenues" means revenues derived by CPSI or any one or more of its affiliates from the granting of rights under the patents and patent applications set forth on Schedule A to any one or more other parties, provided, however, that "Royalty Revenues" shall not include reimbursement for development and clinical expenses incurred following the date of granting of such rights. [REDACTED]
[REDACTED]
[REDACTED]

independent certified public accountant, at the expense of the designee. Should any such audit show an underpayment of more than ten per cent (10%), CPSI shall bear the expense of such audit. CPSI agrees that the designee may conduct such an audit once in every two calendar years. Any payment made by CPSI pursuant to paragraph 6 of this Agreement shall be accompanied by a written statement indicating what the payment was for and how it was

quarter in which there are no such payments owing. CPSI shall so indicate to the designee in writing.

7. Any payment made by CPSI pursuant to paragraph 6 of this Agreement shall be accompanied by a written statement indicating what patent(s) or patent application(s) present claims pursuant to which the royalty payment was made. [REDACTED]

owing, CPSI may satisfy its obligations under this paragraph by so indicating in writing to the designee.

8. The parties recognize that to the extent either believes the other has outstanding monetary obligations to the party, or any performance obligations other than those recited herein, in consideration of the rights and privileges secured by this Agreement, each party agrees that any such claim or entitlement is forever set aside, extinguished or otherwise satisfied such that there is no claim by either party against the other save for those set forth in this Agreement.

9. The Institute represents to CPSI that to the best of its knowledge, no third party has any rights in the patents and patent applications set forth in Schedule A that would interfere in any way with CPSI's exclusive enjoyment and exercise thereof.

10. This Agreement is entire and represents the complete understanding of the parties. It may not be altered save by a written document executed by the parties, or representatives therefor, dated subsequent to the execution date of this Agreement.

11. This Agreement is subject to, and to be interpreted pursuant to, the laws of the State of Pennsylvania and the United States of America, in each case, without regard to the principals of conflicts of law. In the event any provision of this Agreement is found to be void or unenforceable at law, all other provisions not so found shall remain in full force and effect.

Cytokine PharmaSciences, Inc.

By: D. J. Williamson
President & CEO

8/28/02
Date

The Picower Institute for Medical Research

By: Peter Cane

8/28/02
Date

SCHEDULE A

Format of information supplied for each patent or patent application listed:

Descriptive name of "family" of related applications (US or Foreign docket)			
CPSI docket number	Application #	Title of application or patent	Status or patent #
	Filing date		Issue date

Multivalent guanylhydrazone-related cases (US docket)			
0101	08/164,540	Guanylhydrazones and their use to treat cachexia and related conditions	abandoned
	21JAN1994		
0102	08/315,170	Guanylhydrazones and their use to treat inflammatory conditions	# 5,599,984
	29SEP1994		04FEB1997
0103	08/463,568	Guanylhydrazones and their use to treat inflammatory conditions	# 5,750,573
	05JUN1995		12MAY1998
0103 A	08/472,003	Guanylhydrazones and their use to treat inflammatory conditions	# 6,180,676
	06JUN1995		30JAN2001
0103 B	08/472,919	Guanylhydrazones and their use to treat inflammatory conditions	# 6,022,900
	06JUN1995		06FEB2000
0103 C	08/471,696	Guanylhydrazones and their use to treat inflammatory conditions	# 5,753,684
	06JUN1995		19 MAY1998
0103 D	08/471,305	Guanylhydrazones and their use to treat inflammatory conditions	# 6,008,255
	06JUN1995		28DEC1999
0103 E	08/471,124	Guanylhydrazones and their use to treat inflammatory conditions	# 5,859,062
	06JUN1995		12JAN1999
0103 F	08/470,076	Guanylhydrazones and their use for treating inflammatory conditions	abandoned
	06JUN1995		
0103 G	08/472,004	Guanylhydrazones and their use to treat inflammatory conditions	# 5,849,794
	06JUN1995		15DEC1998

#3652846 v1 - CPSI Schedule A Final.doc DATE \@ "MMMM d, yyyy (h:mmAM/PM)"

0103 H	08/479,050 06JUN1995	Guanylhydrazones and their use to treat inflammatory conditions	# 6,248,787
			19JUN2001
0103 I	08/471,711 06JUN1995	Guanylhydrazones and their use to treat inflammatory conditions	abandoned
0103J	09/824,217	Guanylhydrazones and their use to treat inflammatory conditions	pending

#3652846 v1 - CPSI Schedule A Final.doc DATE \@ "MMMM d, yyyy (h:mmAM/PM)"

	03APR2001		
0104	08/632,305 15APR1996	Guanylhydrazones and their use to treat inflammatory conditions	# 5,854,289 29DEC1998
0105 P	60/031,061 15NOV1996	Treatment of disorders related to T cell activation by interfering with p38 MAP kinase pathway	converted
0105	08/970,973 14NOV1997	Guanylhydrazones useful for treating diseases associated with T cell activation	# 6,143,728 07NOV2000
0106A	09/705,581 02NOV2000	Guanylhydrazones useful for treating diseases associated with T cell activation	pending
0106	08/780,311 08JAN1997	Complexes and combinations of fetuin with therapeutic agents	#6,319,894 20NOV2001
end of section			

Multivalent guanylhydrazone-related cases (Foreign docket)			
0102 WO	US95/00828 19JAN1995	Guanylhydrazones for treating inflammatory conditions	filed national
0102 AU	18350/95 19JAN1995	Guanylhydrazones for treating inflammatory conditions	# 683,999 19MAR1998
0102 CA	2,181,689 19JAN1995	Guanylhydrazones for treating inflammatory conditions	pending
0102 CN	95192171.1 20SEP1996	Guanylhydrazones for treating inflammatory conditions	pending
0102 EP	95910110.6 19JAN1995	Guanylhydrazones for treating inflammatory conditions	pending
0102 JP	07-519690 22JUL1996	Guanylhydrazones for treating inflammatory conditions	pending
0102 MX	96 02874 19JUL1996	Guanylhydrazones and their use for treating inflammatory conditions	pending
0102 NZ	281,400 19JAN1995	Guanylhydrazones and their use for treating inflammatory conditions	# 281400 05FEB1999

#3652846 v1 - CPSI Schedule A Final.doc DATE \@ "MMMM d, yyyy (h:mmAM/PM)"

0102A NZ	330610	Guanylhydrazones and their use for treating inflammatory conditions	pending
	19JAN1995		
0105 WO	US97/20670	Guanylhydrazones useful for treating diseases associated with T-cell activation	filed national
	14NOV1997		
0105 AU	54360/98	Guanylhydrazones useful for treating diseases associated with T-cell activation	pending
	14NOV1997		

#3652846 v1 - CPSI Schedule A Final.doc DATE \@ "MMMM d, yyyy (h:mmAM/PM)"

0105 CA	2,271,693 14NOV1997	Guanylhydrazones useful for treating diseases associated with T-cell activation	pending
0105 EP	97948263.5 14NOV1997	Guanylhydrazones useful for treating diseases associated with T-cell activation	pending
0105 JP	10-522801 14NOV1997	Guanylhydrazones useful for treating diseases associated with T-cell activation	pending
0106 WO	US98/00390 08JAN1998	Complexes and combinations of fetuin with therapeutic agents	filed national
0106 AU	60194/98 08JAN1998	Complexes and combinations of fetuin with therapeutic agents	pending
0106 CA	2,277,034 08JAN1998	Complexes and combinations of fetuin with therapeutic agents	pending
0106 EP	98903416.0 08JAN1998	Complexes and combinations of fetuin with therapeutic agents	pending
0106 JP	10-531117 08JAN1998	Complexes and combinations of fetuin with therapeutic agents	pending
end of section			

Macrophage Migration Inhibitory Factor-related cases (US docket)			
0201	08/063,399 17MAY1993	Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity	abandoned
0202	08/243,342 16MAY1994	Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity	abandoned
0203	08/462,350 05JUN1995	Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity	abandoned
0203 A	08/470,901 06JUN1995	Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity	abandoned

0203 B	08/479,901	Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity	abandoned
	06JUN1995		
0203 C	08/479,090	Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity using soluble MIF receptor	abandoned
	06JUN1995		
0203 D	08/471,705	Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity	pending
	06JUN1995		
0203 E	08/479,092	Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity	abandoned
	06JUN1995		
0203 F	08/471,546	Combination method for treating diseases caused by cytokine-mediated toxicity	#6,030,615
	06JUN1995		29FEB2000
0203 G	08/471,586	Diagnostic assays for MIF	#6,080,407
	06JUN1995		27JUN2000
0203 H	09/557,823	Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity	pending
	25APR2000		
0204	08/602,929	Screening assay for the identification of inhibitors of macrophage migration inhibitory factor	pending
	16FEB1996		
0205	08/738,947	Therapeutic uses of factors which inhibit or neutralize MIF activity	pending
	24OCT1996		
0206 P	60/162,467	Compounds having MIF antagonist activity	converted
	29OCT1999		
0206	09/699,258	Compounds having MIF antagonist activity	pending
	27OCT2000		

0209 WO	US97/02448 14FEB1997	Screening assay for the identification of inhibitors of macrophage migration inhibitory factor	filed national
0204 CA	CA2218364 14FEB1997	Screening assay for the identification of inhibitors of macrophage migration inhibitory factor	pending
0204 EP	97905997.9 24OCT1997	Screening assay for the identification of inhibitors of macrophage migration inhibitory factor	pending
0204 JP	9-529544 14FEB1997	Screening assay for the identification of inhibitors of macrophage migration inhibitory factor	pending
0205 WO	US97/19924 24OCT1997	Use of macrophage migration inhibitory factor antagonists for anti-cancer therapy	filed national
0205 AU	51014/98 24OCT1997	Use of macrophage migration inhibitory factor antagonists for anti-cancer therapy	pending
0205 CA	2,267,069 24OCT1997	Use of macrophage migration inhibitory factor antagonists for anti-cancer therapy	pending
0205 EP	97913963.1 24OCT1997	Use of macrophage migration inhibitory factor antagonists for anti-cancer therapy	pending
0205 JP	10-519750 24OCT1997	Use of macrophage migration inhibitory factor antagonists for anti-cancer therapy	pending
0206 WO	US00/29554 29OCT2000	Compounds having MIF antagonist activity	pending
0207 WO	US01/23399 26JUL2001	Compounds having MIF antagonist activity	pending
0208 WO	pending 14JAN2002	Regulation of the CTL response by macrophage migration inhibitory factor	pending
end of section			

NLS-based HIV inhibitor-related cases (US docket)			
0301	08/369,830	Pyrimidine compounds and methods of use to derivatize neighboring lysine residues in proteins under physiological conditions	# 5,574,040

#3652846 v1 - CPSI Schedule A Final.doc DATE \@ "MMMM d, yyyy (h:mmAM/PM)"

0207	pending	Compounds having MIF antagonist activity	pending
	26JUL2000		
0208P	60/260,914	Regulation of the CTL response by macrophage migration inhibitory factor	converted
	12JAN2001		
0208	60/260,322	Regulation of the CTL response by macrophage migration inhibitory factor	pending
	14JAN2002		
0210P	60/296,478	Isoxazoline compounds having MIF antagonist activity	pending
	08JUN2001		
0211P	60/279,435	Methods and compositions for using MHC Class II invariant polypeptide chain as a receptor for MIF	pending
	29MAR2001		
0212P	60/340956	MIF knockout mouse	pending
	19DEC2001		
0213P	60/341832	Functional MIF promoter polymorphism in Rheumatoid Arthritis	pending
	21DEC2001		
end of section			

Macrophage Migration Inhibitory Factor-related cases (Foreign docket)			
0202 WO	US94/05433	Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity	filed national
	16MAY1994		
0202 AU	66345/94	Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity	# 692159
	5SEP1998		05NOV1998
0202 CA	2,163,211	Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity	pending
	16MAY1994		
0202 EP	94916785.2	Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity	pending
	16MAY1994		
0202 JP	6-525764	Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity	pending
	16MAY1994		

#3652846 v1 - CPSI Schedule A Final.doc DATE \@ "MMMM d, yyyy (h:mmAM/PM)"

	06JAN1995		12NOV1996
0302	08/463,405	Compounds and methods of use to derivatize neighboring lysine residues in proteins under physiological conditions	# 5,733,932
	05JUN1995		31MAR1998
0302 A	08/471,797	Compounds and methods of use to derivatize neighboring lysine residues in proteins under physiological conditions	# 5,703,086
	06JUN1995		30DEC1997
0302 B	08/470,103	Compounds and methods of use to derivatize neighboring lysine residues in proteins under physiological conditions	# 5,620,983
	06JUN1995		15APR1997
0303	08/584,857	Compounds for treating infectious diseases	# 5,840,893
	05JAN1996		24NOV1998
0304	08/732,653	Compounds and methods of use to treat infectious diseases	#6,297,263
	15OCT1996		02OCT2001
0304A	09/887,020	Compounds and methods of use to treat infectious diseases	pending
	25JUN2001		
0305	08/912,076	HIV nuclear localization inhibitors	# 5,808,068
	15AUG1997		15SEP1998
0306	08/911,883	HIV matrix protein tyrosine position 29 pocket binders	# 5,849,793
	15AUG1997		15DEC1998
end of section			

NLS-based HIV inhibitor-related cases (Foreign docket)			
0303 WO	US96/00486	Compounds and methods of use to treat infectious diseases	filed national
	05JAN1996		
0303 AU	47569/96	Compounds and methods of use to treat infectious diseases	#715,844
	05JAN1996		25MAY2000
0303 CA	2,218,561	Compounds and methods of use to treat infectious diseases	pending
	05JAN1996		
0303 EP	98903481.8	Compounds and methods of use to treat infectious diseases	pending
	05JAN1996		
0304 WO	97/19071	Compounds and methods of use to treat infectious diseases	filed national

#3652846 v1 - CPSI Schedule A Final.doc DATE \@ "MMMM d, yyyy (h:mmAM/PM)"

	15OCT1997		
0304 JP	10-518660 15OCT1997	Compounds and methods of use to treat infectious diseases	pending
0305 WO	US98/16814 13AUG1998	HIV nuclear localization inhibitors	filed national
0305 AU	89054/98 13AUG1998	HIV nuclear localization inhibitors	pending
0305 CA	2300424 13AUG1998	HIV nuclear localization inhibitors	pending
0305 EP	98940874.5 13AUG1998	HIV nuclear localization inhibitors	pending
0305 JP	2000-509697 13AUG1998	HIV nuclear localization inhibitors	pending
0306 WO	US98/16923 14AUG1998	HIV matrix protein tyrosine position 29 pocket binders	filed national
0306 AU	90201/98 14AUG1998	HIV matrix protein tyrosine position 29 pocket binders	pending
0306 CA	2,300,876 14AUG1998	HIV matrix protein tyrosine position 29 pocket binders	pending
0306 EP	98942068.2 14AUG1998	HIV matrix protein tyrosine position 29 pocket binders	pending
0306 JP	2000-509689 14AUG1998	HIV matrix protein tyrosine position 29 pocket binders	pending
end of section			

Fibrocyte-related cases (US docket)			
0401	08/023,290 26FEB1993	Blood-borne mesenchymal cells	# 5,654,186 05AUG1997
0401 A	08/487,116 07JUN1995	Blood-borne mesenchymal cells	# 6,174,526 16JAN2001

#3652846 v1 - CPSI Schedule A Final.doc DATE \@ "MMMM d, yyyy (h:mmAM/PM)"

0401 B	08/488,241	Blood-borne mesenchymal cells	# 5,846,796
	07JUN1995		08DEC1998
0402	08/488,111	Blood-borne mesenchymal cells	# 5,804,448
	07JUN1995		08SEP1998
0402 A	08/488,112	Blood-borne mesenchymal cells	#6,054,121
	07JUN1995		25APR2000
0403 P	60/031,259	Process for Isolating blood-borne fibrocytes	converted
	15NOV1996		
0403	08/970,971	Process for isolating blood-borne fibrocytes	abandoned
	14NOV1997		
0404	08/828,415	Fibrocyte-based vaccine formulations	pending
	28MAR1997		
0405P	60/294,956	Peripheral blood fibrocytes: Differentiation pathway and migration to wound sites	pending
	04JUN2001		
end of section			

Fibrocyte-related cases (Foreign docket)			
0401 WO	US94/02850	Blood-borne mesenchymal cells	filed national
	16MAR1994		
0401 AU	65984/94	Blood-borne mesenchymal cells	# 6,934,41
	16MAR1994		05NOV1998
0401 CA	2185539	Blood-borne mesenchymal cells	pending
	16MAR1994		
0401 CN	94195107.3	Blood-borne mesenchymal cells	pending
	16MAR1994		
0401 EP	94913910.9	Blood-borne mesenchymal cells	pending
	02AUG1995		
0401 JP	7-523995	Blood-borne mesenchymal cells	pending
	15MAR1994		
0401 KR	7051171996	Blood-borne mesenchymal cells	pending

		19SEP1996	
0401 NZ	265435	Blood-borne mesenchymal cells	# 265,435
	16MAR1994		08JAN1998
0404 WO	US98/06054	Fibrocyte-based cellular therapy formulations	filed national
	27MAR1998		
0404 CA	2,284,471	Fibrocyte-based cellular therapy formulations.	pending
	27MAR1998		
0404 EP	98913216.2	Fibrocyte-based cellular therapy formulations.	pending
	27MAR1998		
0404 IL	132081	Fibrocyte-based cellular therapy formulations.	pending
	27MAR1998		
0404 JP	10-541844	Fibrocyte-based cellular therapy formulations.	pending
	27MAR1998		
0404 MX	988728	Fibrocyte-based cellular therapy formulations.	pending
	27MAR1998		
end of section			

Cyclophilin receptor-related HIV inhibition-related cases (US and foreign dockets)			
0501 P	60/013,185	Treatment of HIV infection by interfering with host cell cyclophilin receptor activity	converted
	12MAR1996		
0501	08/615,933	Treatment of HIV infection by interfering with host cell cyclophilin receptor activity	# 5,840,305
	14MAR1996		24NOV1998
0501 WO	US97/03819	Treatment of HIV infection by interfering with host cell cyclophilin receptor activity	filed national
	12MAR1997		
0501 AU	25811/97	Treatment of HIV infection by interfering with host cell cyclophilin receptor activity	pending
	12MAR1997		
0501 AU A	42717/00	Treatment of HIV infection by interfering with host cell cyclophilin receptor activity	pending
	28JUN2000		
0501 CA	2248192	Treatment of HIV infection by interfering with host cell cyclophilin receptor activity	pending
	12MAR1997		

#3652846 v1 - CPSI Schedule A Final.doc DATE \@ "MMMM d, yyyy (h:mmAM/PM)"

0501 EP	97917517.1	Treatment of HIV infection by interfering with host cell cyclophilin receptor activity	pending
	10OCT1997		
0501 JP	9-532773	Treatment of HIV infection by interfering with host cell cyclophilin receptor activity	pending
	14SEP1998		
0502	09/637,033	Treatment of HIV Infection by Interfering with host cell cyclophilin receptor activity	pending
	10AUG2000		
0502 WO	US01/25178	Treatment of HIV-1 infection and inflammatory disease using cyclophilin receptor antagonists	pending
	10AUG2001		
end of section			

Vaccine Adjuvant For Potentiating Immunogenicity			
0701	08/827,345 26MAR1997	Vaccine Adjuvant	5,849,307 15DEC1998
IPFK2 and the Warburg effect-related cases (US and foreign dockets)			
0901	08/961,578	Inducible phosphofructokinase and the Warburg effect	pending
	31OCT1997		
0902	09/183,846	Inducible phosphofructokinase and the Warburg effect	# 6,255,046
	30OCT1998		03JUL2001
0902A	09/570,216	Inducible phosphofructokinase and the Warburg effect	pending
	25SEP2000		
0903 P	60/130,049	Synthetic process for five-membered polyols and substituted sugar analogs	converted
	19APR1999		
0903	09/556,147	Synthetic process for highly functionalized carbocyclic polyols and substituted sugar analogs	pending
	19APR2000		
0902 WO	US98/23155	Inducible phosphofructokinase and the Warburg effect	filed national
	30OCT1998		
0902 AU	13707/99	Inducible phosphofructokinase and the Warburg effect	pending
	30OCT1998		
0902 CA	2308091	Inducible phosphofructokinase and the Warburg effect	pending
	30OCT1998		

#3652846 v1 - CPSI Schedule A Final.doc DATE \@ "MMMM d, yyyy (h:mmAM/PM)"

0902 EP	98957451.2 30OCT1998	Inducible phosphofructokinase and the Warburg effect	pending
0902 IL	pending 30OCT1998	Inducible phosphofructokinase and the Warburg effect	pending
0902 JP	2000518978 30OCT1998	Inducible phosphofructokinase and the Warburg effect	pending
0903 WO	US00/10880 19APR2000	Synthetic process for highly functionalized carbacyclic polyols and substituted sugar analogs	pending
end of section			

Amyloidosis-based disease-related cases (US docket)			
1501 P	60/341,255 20DEC2001	Apomorphine inhibitors of amyloid-beta fibril formation and their use in amyloidosis-based disease	pending

#3652846 v1 - CPSI Schedule A Final.doc DATE \@ "MM\MM d, yyyy (h:mmAM/PM)"